Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)

Study identifier:BY217/M2-124

ClinicalTrials.gov identifier:NCT00297102

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Effect of roflumilast on exacerbation rate in patients with COPD. The AURA Study

Medical condition

Chronic obstructive pulmonary disease (COPD)

Phase

Phase 3

Healthy volunteers

No

Study drug

Roflumilast, Placebo

Sex

All

Actual enrollment

1523

Study type

Interventional

Age

40 Years +

Date

Study Start Date: 01 Feb 2006
Primary Completion Date: 01 Jul 2008
Study Completion Date: 01 Sept 2008

Study design

Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria